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Abstract  
30 years old, unmarried girl with above knee amputation of right lower limbs since 1998 as 
radical treatment for Osteosarcoma of upper tibia with no systemic or local recurrence after 
oncological treatment until now. 
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Introduction 
History of present illness  
The condition started before 21 years when she felt pain   & swelling in her right 
foot,on examination, we suspect bone tumor as by x ray there was periosteal reaction 
,in the 2nd metatarsal bone with destruction of the cortex, operation was done 
(Excisional biopsy) to excise 2nd metatarsal bone as a whole with tumor sent for 
Histopathology which revel Osteosarcoma , so we decided to do an amputation of the 
right foot (above ankle) but the relative refused to do an amputation.  
 
After 9 months she came to an orthopedic surgeon with another lesion in same 
side of the limb but in the upper third of right tibia with lytic lesion   & destruction of 
the cortex so bone metastases suspected   & another biopsy done   & same result of 
Osteosarcoma proved, so we decided it do above knee amputation after complete 
survey if there was another metastases which was negative, so amputation done   &
sent for histopathology   & also the result was Osteosarcoma after that the surgeon  
sent her to oncologist doctor for chemotherapy   & she received 6 course of 
chemotherapy (ADM 50mg/m2& cisplatin 50mg/m2 & every 3 weeks) followed 
ARTICLE INFO 
Submission date: 29 / 5 2019 
Acceptance date: 19/ 11 / 2019 
Publication date: 31/ 12 / 2019 
Journal of University of Babylon for Pure and Applied Sciences, Vol. (27), No. (6): 2019 
 
277 
 
closely by him for recurrence but till now there are no sign of metastases locally or 
distally. 
 
Background 
 Osteosarcoma is the most common primary malignant bone tumor (1, 2). It is an 
ancient disease that is still incompletely understood. Osteosarcoma is thought to arise 
from primitive mesenchymal bone-forming cells, and its histologic hallmark is the 
production of malignant osteoid. Other cell populations may also be present, as these 
types of cells may also arise from pleuripotential mesenchymal cells, but any area of 
malignant bone in the lesion establishes the diagnosis as Osteosarcoma. 
 Osteosarcoma is a lethal form of musculoskeletal cancer that most commonly causes 
death of patients from pulmonary metastatic disease. (3, 4)  . Most osteosarcomas arise 
as solitary lesions within the fastest growing areas of the long bones of children. The 
affected areas are the distal femur, the proximal tibia, and the proximal humerus, but 
virtually any bone can be affected. 
 
Pathophysiology 
Osteosarcoma is a bone tumor and can occur in any bone, usually in the extremities of 
long bones near metaphyseal growth plates. The most common sites are as follow( 14 ): 
 Femur (42%, 75% of which are in the distal femur)  
 Tibia (19%, 80 % ,of which are in the proximal tibia)  
 Humerus (10%, 90% of which are in the proximal Humerus)  
 Skull and jaw (8%)  
 Pelvis (8%)  
A number of variants of Osteosarcoma exist, including conventional types 
(osteoblastic, chondroblastic, and fibroblastic), telangiectatic ,multifocal, parosteal, 
and periosteal. This article only addresses conventional Osteosarcoma (often referred 
to simply as Osteosarcoma).   
The cause of bone tumors is unknown.(3,4,5,6,7) They often arise in areas of rapid 
growth. Possible causes include: Inherited genetic mutations ,Radiation  & Trauma 
 But in most cases no specific cause is found. 
Cancers that start in the bones are referred to as primary bone tumors .Cancers 
that start in another part of the body (such as the breast ,lungs, or colon) are not 
considered bone tumors  
The most common cancers that spread to the bone are cancer of the: Breast, 
Kidney ,Lung ,Prostate  , Thyroid , these forms of cancer usually affect older people.  
 
Epidemiology 
In the United States, the incidence of Osteosarcoma is 400 cases per year (4.8 
per million population < 20 years). The overall 5-year survival rate for patients 
diagnosed between 1974 and 1994 was 63% (59% for males, 70% for females) . 
The incidence is slightly higher in blacks than in whites. Data from the National 
Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER)Pediatric 
Monograph 1975-1995, are as follows: (8) 
Blacks - 5.2 cases per million per year ) < 20   years)  
Whites - 4.6 cases per million per year  
The incidence of Osteosarcoma is slightly higher in males than in females. In 
males, it is 5.2 per million per year; in females, it is 4.5 per million per year . 
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Osteosarcoma is very rare in young children (0.5 cases per million per year in 
children < 5 years). However, the incidence increases steadily with age, rising more 
dramatically in adolescence in correspondence with the adolescent growth spurt, as 
follows: (8) 
 Age 5 -  9  years -- 2.6  (black) or 2.1 (white) cases per million per year  
 Age 10-14 years -- 8.3  (black) or  7   (white) cases per million per year  
 Age 15-19 years -- 8.9  (black) or 8.2 (white) cases per million per year 
 
 
Prognosis 
The present understanding of outcome and prognosis for osteosarcoma is driven 
by certain serum markers, clinical staging, and histologic response to 
chemotherapeutic agents. [9] 
 
According to SEER data for 1973-2004, the overall relative 5-year survival 
rates were as follows [8] : 
 Age < 25 years - 61.6% (females, 65.8%; males, 58.4%) 
 Age 25-59 years - 58.7% (females, 64%; males, 54.6%) 
 Age 60-85+ years - 24.2% (females, 27.0%; males, 19.9%), with a drastic 
drop with advancing age (from ~50% for patients in their 50s to 17% for those in their 
middle-to-late 60s and to 10.8% for those aged 80 years or older)  
Patients with an elevated ALP (Alkaline Phosphatase) at diagnosis are more 
likely to have pulmonary metastases. In patients without metastases, those with an 
elevated LDH are less likely to do well than are those with a normal LDH (Lactate 
Dehydrogenase). 
 
Discussion 
Comparative Studies 
1-Survival in high-grade osteosarcoma: improvement over 21 years at a single 
institution.(10) 
With a median follow-up of 12 years (5-25 years), 754 patients (51.7%) are 
alive, of whom 613 continuously disease free. Survival at 5, 10, and 15 years is 57%, 
52%, and 51%, respectively. Patients candidates for clinical trials have a survival rate 
of 68%, 64%, and 61%, respectively. Survival for the other patients is 30%, 25%, and 
24%, respectively. Trend (joinpoint statistical analysis at real 5-year follow-up) shows 
a yearly statistically significant improvement of 1.31% (95% confidence interval 
0.5% to 2.1%) from 51% for patients treated in 1982 to 68% for those treated in 
2002.. 
2-Trends and variability in survival among patients with osteosarcoma: a 7-year 
update (11) 
 A prognostic score was developed, which was based on the number of the 
following unfavorable characteristics: age younger than 10 years, male sex, tumor 
diameter more than 15 cm, cell type osteoblastic or chondroblastic, duration of 
symptoms 2 months or less, and involvement of the femur or humerus. Patients with 
five or six of these unfavorable characteristics had a very poor survival; in contrast, 
patients with only one or two characteristics had a good outcome.  
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3-Survival, prognosis, and therapeutic response in osteogenic sarcoma. The 
Memorial Hospital experience (12) 
 
 Survival was 77% and 73% at 5 and 10 years, respectively, with continuously 
disease-free survival being 70% and 69%. 
 The risk of local recurrence was almost fivefold higher in tumors of the femur 
than in tumors of other locations (relative risk, 4.6) and, within the femur, was more 
than threefold higher in the proximal femur than in the distal femur (relative risk, 
3.4).. The rate of failure was almost fivefold as high in those with an incomplete 
response to chemotherapy compared with those with a complete response to 
chemotherapy (relative risk, 4.9; 95% confidence interval, 2.2 to 11). Even in those 
patients with minimal or no necrosis in the primary tumor, ultimately 62% and 54% 
were disease-free at 5 and 10 years, respectively. 
4-Survival Data for 648 Patients with Osteosarcoma Treated at One 
Institution(13) 
Survival rate was markedly affected by patient age. The survival rate for the 
patients younger than 20 years was78%, whereas the survival rate for patients from 20 
to 40years was 70% 
 
Conclusion 
Osteosarcoma case was registered for the patient at 9 years old in 1998   & she is 
alive for 21 years became a 30 -years-old in 2019 in Babil province from ( 18686) 
cases of a malignant tumors during the period from (1990 - 2019) 10052 
(53.79%):women    8634 (46.20%)  males,with ratio 1.15: 1 for women: men  
After a referral from respected doctor, who was found a positive biopsy for 
malignant tumor (Osteosarcoma) in her right foot and make an amputation operation 
and then the tumor recurrent below the knee and underwent an amputation above knee 
joint then treated by 6 courses chemotherapy (Cisplatin +  Aderiamycin) every 3 
weeks and she responded well to the treatment and  the tumor did metastasized to  
other organs of the body through regular check-up since 1998 until now (2019).  
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ةــــصلاخلا 
جس ةـضيرملا ةـلاح تلو  اهرمع9  ماع ةـنس1998  اـهرمع تــحبصأو30  ماع ةنس2019 ـح ةـقطنم لـباب ةـــظفاحم يف ي
 ماــملإا)ع(   نم18686 (   نـــــــيب ام ةرـتفلا للاخ ثـيبخ مرو ةلاــح1990 - 2018: يلي امك تناك )-  
10052 (53.79)% :ثاــــــــــــــــــنإ. 
8634 (46.20%).روــــــــــــــــــكذ : 
ةبسنب يأ 1,15  :1  .  لاجرلا : ءاسنلل 
 خلأا نم اـهتلاحإ دـعبو ماظعلا صاصتخا( نميلأا لفسلأا فرطلا مظعب ثــيبخ مروب اهتباصإ دعب مرـتحملاOsteosarcoma )
 مث ترـتب مث نـميلأا قاـسلا يف مروـلا داـع مث ىـنميلا مدقلا رتب ةيلمع اهل يرجاوـيرجأو ةبكرلا لـفسأ مروـلا داـعع اهل تفم قوـف ةيلم لـص
خا روتكدلا لبق نم اهتجلاعم متو ةبكرلاصاصت شلأاب جلاعلاـــ و ةقيمعلا ةعيميكلا جلاـعلابـــسروك تس يواــــ تاـ بزس(+ نيتلا نسياميردا )
 لك3  أ ىلإ مرولا رـشتني ملو جلاـعلل تباجتساو يعاـنص فرـطب تدوز و عـيباسأا تاـصوحفلا للاخ نم ىرخلأا مـسجلا ءاضعـيرودل ة
 ماـع ذنم1998 ( نلآا ىـتح2019 ) . 
 عت الله نيعاد و ةحصلا ماود ةضيرملل نينمتم ىلاةيفاعلا . 
